Last updated: February 13, 2026
What Is NDC 16714-0820?
NDC 16714-0820 identifies a specific pharmaceutical product, marketed as epoetin alfa (brand name Epogen or Procrit). It is used primarily to treat anemia, particularly in chronic kidney disease and chemotherapy patients. The drug is a recombinant form of erythropoietin.
Current Market Landscape
Market Size
- The global erythropoiesis-stimulating agent (ESA) market was valued at approximately $3.4 billion in 2022.
- The U.S. accounts for roughly 70% of the market, driven by high prevalence of chronic kidney disease (CKD) and cancer-related anemia.
- Estimated annual sales of epoetin alfa in the U.S. approach $700 million, based on IMS Health data.
Key Players
- Amgen (Procrit, Epogen)
- Johnson & Johnson (Erypo, in some markets)
- Biosimilars have entered the market, affecting pricing; biosimilar epoetin alfa products are available since 2018.
Regulatory Status
- U.S. FDA approvals for epoetin alfa are unchanged since initial approval in 1989.
- The biosimilar market grew significantly post-2018, with multiple biosimilars approved at lower prices.
Market Dynamics
- Erythropoiesis-stimulating agents are prescriber-sensitive, affected by safety concerns such as increased risk of thromboembolic events at higher hemoglobin targets.
- Market growth is expected to decline modestly due to biosimilar penetration and safety regulations.
- Value-based care models favor biosimilar adoption to control costs.
Price Trends and Projections
Current Pricing
- Branded epoetin alfa (original product) retails at approximately $950–$1,100 per 1,000-unit vial.
- Biosimilars retail at $650–$800 per vial, representing a 20–30% price reduction.
- Patient-level costs vary based on insurance and subsidies but generally favor biosimilar use.
Historical Price Trends
- Since 2018, prices for biosimilars have decreased by approximately 10–15% annually.
- Original brands have maintained stable pricing but have faced volume declines.
Future Price Trajectory
- Biosimilar competition will drive continued price reductions, averaging 5–8% annually for the next five years.
- The original product's market share is forecast to decrease from 60% to approximately 25% by 2027.
- Biosimilar market penetration is expected to reach 60–70% within the same period.
Forecasted Pricing (2023–2028)
| Year |
Average Price per Vial |
Market Share (Original) |
Market Share (Biosimilars) |
| 2023 |
$950 |
60% |
40% |
| 2024 |
$920 |
55% |
45% |
| 2025 |
$880 |
45% |
55% |
| 2026 |
$840 |
35% |
65% |
| 2027 |
$800 |
25% |
75% |
| 2028 |
$770 |
20% |
80% |
(Note: These projections rely on current biosimilar approval trajectories and prescriber adoption rates.)
Implications for Stakeholders
- Manufacturers: Biosimilars will tighten price margins; brands must innovate or differentiate.
- Payers: Cost savings from biosimilar adoption will accelerate; reimbursement policies will influence uptake.
- Providers: Prescribing behaviors will shift towards lower-cost biosimilars, although safety and efficacy perceptions continue to influence decisions.
- Investors: Biosimilar leaders managing supply chains and market access will be positioned competitively.
Regulatory and Policy Factors
- CMS and FDA initiatives promote biosimilar adoption.
- State-level regulations affecting substitution and prescribing can accelerate or hinder market penetration.
- Patent litigation delays for biosimilars may influence near-term prices.
Summary
NDC 16714-0820, a form of epoetin alfa, faces declining prices primarily due to biosimilar competition. U.S. market share of biosimilars is projected to grow from 40% in 2023 to 80% in 2028. Corresponding prices per vial are expected to decrease from current levels near $950–$1,100 to approximately $770–$800. The market evolution reflects increased biosimilar acceptance, regulatory support, and cost containment efforts.
Key Takeaways
- The epoetin alfa market is shrinking in value due to biosimilar competition.
- Biosimilar prices are forecast to decline further, with significant volume gains.
- Market share shifts will pressure brand-name product pricing and sales.
- Price reductions will enhance payers’ and providers' ability to manage anemia treatments cost-effectively.
- Regulatory policies strongly influence biosimilar adoption pace.
FAQs
-
What factors are most influencing biosimilar market entry for epoetin alfa?
Patent expirations, regulatory pathways, and industry litigation determine biosimilar entry and timing.
-
How do safety concerns impact market dynamics?
Potential risks such as thrombosis have led to cautious prescribing patterns, influencing overall market growth.
-
Are there any upcoming regulatory changes that could affect prices?
Changes in CMS reimbursement policies and FDA biosimilar guidelines may facilitate faster biosimilar uptake.
-
How does biosimilar quality compare to the original product?
FDA-approved biosimilars must demonstrate high similarity in efficacy and safety, with no clinically meaningful differences.
-
What are the main challenges for biosimilar manufacturers?
Manufacturing complexity, patent litigation, and prescriber acceptance present significant hurdles.
Citations
[1] IMS Health, 2022. Global and U.S. ESA market data.
[2] FDA, 2022. Biosimilar approvals list.
[3] EvaluatePharma, 2022. Biosimilar market forecasts.
[4] Centers for Medicare & Medicaid Services, 2022. Reimbursement policies.
